Answers are grounded in this paper and cite their sources.
Comparative trial demonstrates pH-responsive drug release in CNS therapeutics, indicating graphene oxide's potential in drug delivery.
Graphene oxide (GO) has emerged as a versatile nanocarrier owing to its large surface area and rich surface chemistry; however, systematic studies correlating drug physicochemical properties with loading and release behavior remain limited, particularly for central nervous system (CNS) therapeutics. Herein, we present a comparative investigation of pH-responsive loading and release of two structurally distinct CNS drugs, d-cycloserine and riluzole, using graphene oxide as a common nanocarrier under identical experimental conditions. Drug loading efficiency and encapsulation efficiency were systematically evaluated as a function of pH, temperature, and initial drug concentration. GO exhibited a higher affinity for d-cycloserine, which is attributed to its greater polarity and hydrogen-bonding capability, whereas riluzole loading was primarily governed by π-π stacking and hydrophobic interactions. Both GO-drug systems displayed pronounced pH-responsive release behavior, with accelerated release under acidic conditions and sustained release at physiological pH. In vitro cytocompatibility studies using SH-SY5Y neuroblastoma cells demonstrated excellent biocompatibility for all formulations. This comparative study elucidates the critical role of drug chemistry in governing GO-drug interactions and provides design insights for graphene-based nanocarriers tailored for CNS drug delivery.
No takes yet. Share an insight, caveat, or question.
Nawrin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: